Literature DB >> 7066601

Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

J S Millar, E M Vaughan Williams.   

Abstract

1 The effects of cibenzoline (UP 339-01), a new anti-arrhythmic drug, have been investigated in various cardiac tissues. 2 UP 339-01 produced a bradycardia, due partly to prolongation of the intracellularly recorded sinus node action potential duration (APD) and partly to depression of the maximum rate of depolarization (MRD). The slope of the slow diastolic depolarization was not significantly reduced. 3 UP 339-01 was not a beta-adrenoceptor antagonist. 4 UP 339-01 was negatively inotropic, and shifted the relation between [Ca2+]o and force of contractions to the right, and increased A-H conduction time. It was concluded that UP 339-01 restricted slow inward current. 5 In all cardiac tissues depolarized by fast inward current, UP 339-01 caused a reduction in MRD and conduction velocity. The reduction was similar in atrial muscle, His and terminal Purkinje fibres, but in papillary muscle the effect was about half as great. On desheathed frog nerve UP 339-01 had a local anaesthetic potency slightly greater than that of procaine. 6 APD was significantly prolonged in a dose-related manner in ventricular muscle but to a lesser extent in the bundle of His and atrial tissue. In terminal Purkinje fibres APD50 and APD90 were unaltered, but the transient outward current ("notch') was abolished, resulting in a lengthening of APD20. 7 The effective and functional refractory periods of the A-V node and right bundle branch were both lengthened by UP 339-01 in a dose-related manner, and the difference between them was greatly increased. 8 UP 339-01 (2.63 microM) completely prevented the shortening of APD90 induced by hypoxia, and the shortening of APD50 and APD20 was much attenuated. There was no protection against hypoxic depression of contractions. 9 It was concluded that UP 339-01 is a highly active class 1 anti-arrhythmic agent with additional class 3 and 4 properties.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066601      PMCID: PMC2071575          DOI: 10.1111/j.1476-5381.1982.tb09163.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism.

Authors:  L A Salako; V Williams; J H Wittig
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

2.  Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation.

Authors:  S B Olsson; S Cotoi; E Varnauskas
Journal:  Acta Med Scand       Date:  1971-11

3.  Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride.

Authors:  M B Rosenbaum; P A Chiale; D Ryba; M V Elizari
Journal:  Am J Cardiol       Date:  1974-08       Impact factor: 2.778

4.  [Medical therapy of auricular flutter].

Authors:  C Ferrero; M Benabderhamane
Journal:  G Ital Cardiol       Date:  1972

5.  Monophasic action potential of right human atrium during atrial flutter and after conversion to sinus rhythm. Argument for re-entry theory.

Authors:  S Gavrilescu; S Cotoi
Journal:  Br Heart J       Date:  1972-04

6.  Clinical efficacy of amiodarone as an antiarrhythmic agent.

Authors:  M B Rosenbaum; P A Chiale; M S Halpern; G J Nau; J Przybylski; R J Levi; J O Lázzari; M V Elizari
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778

7.  The relevance of beta-receptor blockade to ouabain-induced cardiac arrhythmias.

Authors:  A N Dohadwalla; A S Freedberg; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1969-06       Impact factor: 8.739

8.  The effect of altered thyroid state on atrial intracellular potentials.

Authors:  A S Freedberg; J G Papp; E M Williams
Journal:  J Physiol       Date:  1970-04       Impact factor: 5.182

9.  The effect of amiodarone, a new anti-anginal drug, on cardiac muscle.

Authors:  B N Singh; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

10.  Differential actions on rabbit nodal, atrial, Purkinje cell and ventricular potentials of melperone, a bradycardic agent delaying repolarization: effects of hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-01       Impact factor: 8.739

View more
  21 in total

Review 1.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

2.  The efficacy of cibenzoline for reducing the left ventricular pressure gradient of hypertrophic obstructive cardiomyopathy: A case report.

Authors:  Hideki Igarashi
Journal:  J Med Ultrason (2001)       Date:  2003-06       Impact factor: 1.314

3.  Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Tai Sekine; Masao Daimon; Rei Hasegawa; Kiyomi Teramoto; Takayuki Kawata; Nobuhiro Tanaka; Yasuhiro Takei; Kenji Takazawa; Katsuya Yoshida; Issei Komuro
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

4.  Pharmacokinetics of oral cibenzoline in arrhythmia patients.

Authors:  R K Brazzell; W A Colburn; K Aogaichi; A J Szuna; J C Somberg; N Carliner; J Heger; J Morganroth; R A Winkle; P Block
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

5.  Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.

Authors:  Y Tabuchi; H Yashiro; S Hoshina; S Asano; N Takeguchi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Ventricular and atrial electrophysiological effects of a IC antiarrhythmic drug, cibenzoline, in the innervated dog heart. Role of sodium and calcium channels.

Authors:  Q Timour; J F Aupetit; J Loufoua-Moundanga; L Bertrix; M Freysz; G Faucon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

7.  Effect of food on cibenzoline bioavailability.

Authors:  J W Massarella; H P Blumenthal; T Silvestri; A Lin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Cibenzoline inhibits diazoxide- and 2,4-dinitrophenol-activated ATP-sensitive K+ channels in guinea-pig ventricular cells.

Authors:  T Sato; B Wu; S Nakamura; T Kiyosue; M Arita
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

9.  Effects on transmembrane action potential, slow inward current and force of contraction in ventricular cardiac muscle of BRL 31660, a new antiarrhythmic drug with class I and class IV activity.

Authors:  R Brückner; W Schmitz; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-03       Impact factor: 3.000

Review 10.  Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.

Authors:  D W Harron; R N Brogden; D Faulds; A Fitton
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.